Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
|
|
- Frederica Harrison
- 8 years ago
- Views:
Transcription
1 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC) expressing activating mutations of EGFR tyrosine kinase through a provisional agreement with AstraZeneca Limited. amend the funding criteria for erlotinib (Tarceva) such that it would no longer be funded as a second line treatment option for patients with NSCLC disease known to be negative for activating mutations of EGFR tyrosine kinase. This proposal would require that patients with advanced non-squamous NSCLC undergo testing for the presence of activating mutations of EGFR tyrosine kinase in order to access funding for first or second line tyrosine kinase inhibitors. The proposal is consistent with advice from the Pharmacology and Therapeutics Advisory Committee (PTAC) and its Cancer Treatments Subcommittee. Overall, if implemented, the proposal is expected to increase the health gains for lung cancer patients from EGFR tyrosine kinase inhibitor treatments and be cost saving to the Combined Pharmaceutical Budget and cost saving to DHBs in the medium to longer term, taking into account the anticipated changes in patient treatment pathways and the costs to DHBs of providing EGFR testing for all patients with locally advanced, or metastatic, unresectable, non-squamous NSCLC. Further details of this proposal, including how to provide feedback and background information, can be found below and on the following pages. Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm Thursday, 14 June 2012 to: Jackie Evans Therapeutic Group Manager PHARMAC jackie.evans@pharmac.govt.nz Fax: Post PO Box , Wellington 6143 All feedback received before the closing date will be considered by PHARMAC s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. A T Page 1 of 6
2 Details of the proposal In relation to gefitinib (Iressa): Iressa 250 mg tablets would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 August The following prices and subsidies would apply (all prices are ex-manufacturer and exclude GST): Brand Pharmaceutical Presentation Pack size Price and subsidy Iressa gefitinib tab 250 mg 30 $1, Iressa would be funded subject to Special Authority criteria as follows: Gefitinib - Retail Pharmacy Specialist - Special Authority Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1. All of the following: 1.1 Patient has treatment naïve locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and 1.2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and 1.3 Gefitinib is to be given for a maximum of 3 months; or 2. The patient received gefitinib treatment prior to 1 August 2012 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. Renewal application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. Gefitinib would be listed on the National Preferred Medicine List (PML) from the date of its implementation (currently estimated to be 1 July 2013). Any restrictions in the PML applying to the prescribing and dispensing of gefitinib will be no more restrictive than those applying to the listing of gefitinib in Section B of the Pharmaceutical Schedule. Iressa would have subsidy and delisting protection until 1 January In relation to erlotinib hydrochloride (Tarceva): Erlotinib hydrochloride (Tarceva) 100mg and 150 mg tablets would remain listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at the current prices and subsidies. Tarceva would remain subject to a confidential rebate which reduces the net price and subsidy paid by the Funder. Tarceva would maintain its current subsidy and delisting protection until 1 December A T Page 2 of 6
3 The Special Authority criteria applying to all presentations of Tarceva in Section B of the Pharmaceutical Schedule would be amended as follows from 1 January 2014 (additions in bold): Erlotinib hydrochloride - Retail Pharmacy Specialist - Special Authority Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and 2 Patient has documented disease progression following treatment with first line platinum based ; and 3 Either: 3.1 All of the following The patient has non-squamous NSCLC; and Documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and The patient has not received prior treatment with gefitinib; or 3.2 Insufficient biopsy sample available to determine EGFR mutation status or precise histological type; and 4 Erlotinib is to be given for a maximum of 3 months. Renewal application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed. Background The Treatments Gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Roche) are both oral inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. In October 2010 PHARMAC funded erlotinib subject to Special Authority criteria for the second line treatment, after failure of first line platinum based, of patients with advanced, unresectable, NSCLC. Erlotinib has subsidy and delisting protection until 31 December Since erlotinib was funded the correlation between the presence of specific activating mutations in the tyrosine kinase domain of EGFR and increased activity of the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, has become well established. Evidence demonstrates that, compared with standard platinum based, TKI treatment significantly improved progression free survival by around 3-4 months and quality of life in patients with advanced NSCLC expressing EGFR activating mutations. Conversely, patients without EGFR activating mutations treated with a TKI had a significantly shorter time to disease progression compared with standard platinum based, 1.5 months vs 5.8 months respectively. Gefitinib is registered for the first line treatment of patients with NSCLC expressing activating mutations of EGFR tyrosine kinase. However, erlotinib is not currently registered for first line use. This proposal does not prevent PHARMAC from considering in the future the funding erlotinib for first line treatment once it is registered in this setting. A T Page 3 of 6
4 Clinical Advice The funding of EGFR TKI s for NSCLC has been considered by PTAC and its Cancer Treatments Subcommittee (CaTSoP). In summary, they considered that activating mutations in EGFR Tyrosine Kinase were associated with increased activity of TKIs. Members considered that approximately 40% of non-squamous NSCLC would express EGFR mutations but that most squamous cell NSCLC would not express EGFR mutations and would therefore be unlikely to benefit from TKI treatment. PTAC and CaTSoP recommended that gefitinib be funded for the first line treatment of patients with locally advanced, or metastatic, unresectable, non-squamous NSCLC expressing activating mutations of EGFR tyrosine kinase with high priority. They also considered that the current funding criteria for erlotinib were no longer appropriate as they enabled erlotinib to be funded for some patients [those with EGFR negative disease] where it is very unlikely to be effective and for whom standard platinum based treatment would be more efficacious. They recommended that the criteria for erlotinib be amended as proposed with high priority. Relevant published PTAC and CaTSoP minutes can be found on PHARMAC s website at and EGFR testing and Treatment Pathways We consider that approximately 2000 new patients per annum would be diagnosed with lung cancer, approximately one third of whom would present with advanced, unresectable, nonsquamous NSCLC. These patients would undergo EGFR mutation testing in order to determine appropriate funded treatment options. We consider that DHBs would provide EGFR mutation testing for these patients, either in-house or through a third party provider, and have included the estimated costs for such testing in our analysis of the proposal. Approximately half of these patients would test positive and be eligible for first line gefitinib treatment (approximately 240 patients per annum). Those patients whose disease progresses following first line gefitinib treatment would be expected to be treated with platinum-based treatment in the second line setting followed by palliative or best supportive care. Patients who choose not to be tested, or those whose disease is negative for EGFR mutations, would be expected to receive first line platinum-based treatment. Palliative or best supportive care is expected to be provided to those patients whose disease progresses. Patients with indeterminant EGFR results, or insufficient biopsy sample available for testing, would be expected to receive first line platinum-based treatment. Those patients whose disease progresses would remain eligible for erlotinib funding in the second line setting followed by palliative or best supportive care. The current and proposed treatment pathways for patients with advanced NSCLC are outlined in the two diagrams at the end of this letter. NHC work on EGFR testing PHARMAC note that the National Health Committee (NHC) has undertaken and will next week be publishing on its website a Rapid Review of EGFR testing in patients focusing on A T Page 4 of 6
5 clinical safety & effectiveness, value for money, feasibility of adoption in the system and societal and ethical considerations. The purpose of the NHC s work is to enable the NHC to recommend: 1) whether or not EGFR gene testing should be publicly funded to determine eligibility for TKIs in patients with NSCLC in New Zealand and if so, 2) how the service should be provided in the short to medium term. For further information on this work please contact the NHC nhc_info@nhc.govt.nz Financial Impact to DHBs Overall, if implemented, the proposal is expected to increase the health gains for lung cancer patients. The net effect of the proposal would be cost saving to the Combined Pharmaceuticals Budget (CPB) (NPV 5 years, 8%). The proposal would result in incremental costs to DHBs from providing EGFR testing, however, these costs would be more than offset by the savings to the CPB in the medium to long term. Current NSCLC Treatment Pathway Unresectable NSCLC Stage IIIb/IV Erlotinib Palliative Chemotherapy or Best Supportive Care A T Page 5 of 6
6 Proposed Treatment Pathway Unresectable NSCLC Stage IIIb/IV Non-Squamous NSCLC Squamous NSCLC EGFR mutation testing EGFR +ve EGFR status non determinable* EGFR -ve Gefitnib Erlotinib Palliative Chemotherapy or Best Supportive Care *result inconclusive or insufficient biopsy sample available A T Page 6 of 6
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationProposal for rivaroxaban, moxifloxacin, interferon beta-1-beta and other funded treatments for multiple sclerosis
30 September 2010 Proposal for rivaroxaban, moxifloxacin, interferon beta-1-beta and other funded treatments for multiple sclerosis PHARMAC is seeking feedback on a provisional agreement with Bayer New
More informationChanging Paradigms for evaluating costs and benefits of drug treatments. Deven Chauhan Health Economist Office of Health Economics London, UK
Changing Paradigms for evaluating costs and benefits of drug treatments Deven Chauhan Health Economist Office of Health Economics London, UK What do we mean by changing paradigms? Elevating pharmaceutical
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationRapid Review: EGFR gene mutation testing in patients with advanced NSCLC for access to Gefitinib for sector discussion
Rapid Review: EGFR gene mutation testing in patients with advanced NSCLC for access to Gefitinib for sector discussion June 2012 Key words: NSCLC, EGFR, EGFR-TKIs, New Zealand situation, personalised testing,
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationDecisions relating to Multiple Sclerosis treatments
10 October 2014 Decisions relating to Multiple Sclerosis treatments PHARMAC is pleased to announce that, from 1 November 2014, it will: list fingolimod (Gilenya); list natalizumab (Tysabri); and change
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationClinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
More informationSYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationRecruiting now. Could you help by joining this study?
Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate
More informationMedical Policy Manual. Date of Origin: August 2010. Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC)
Medical Policy Manual Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC) Section: Genetic Testing Policy No: 56 Date of Origin: August 2010 Last Reviewed Date: December
More informationHow To Prepare A Meeting For A Health Care Conference
THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App
More informationLung Cancer & Mesothelioma 2011-2015
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
More informationBreakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction
Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationDATE: 28 July 2010 EXECUTIVE SUMMARY. Context and Policy Issues
TITLE: Epidermal Growth Factor Receptor Mutation Analysis in Advanced Non-Small Cell Lung Cancer: Review of Economic Evaluations and Framework for Economic Analyses DATE: 28 July 2010 EXECUTIVE SUMMARY
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationIntroduction of a Standard Drug Formulary in Hospital Authority
Introduction of a Standard Drug Formulary in Hospital Authority PURPOSE This paper seeks Members views on the introduction of a Standard Hospital Authority Drug Formulary ( ) ( Standard Drug Formulary
More informationTreatment of Stage IV Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationErlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche
Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network
More informationThe Cancer Patient Journey. Dr. Jaco Fourie
The Cancer Patient Journey Dr. Jaco Fourie The Cancer Patient Journey Prevention and health promotion Screening Diagnosis and staging Treatment Surveillance and survivorship End of life care The Cancer
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationSecond-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
VOLUME 32 NUMBER 18 JUNE 20 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens Alona Zer and Natasha
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationFARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
More informationLung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationTargeterbare mutationer / biomarkører Status og udfordringer for patologien
Targeterbare mutationer / biomarkører Status og udfordringer for patologien Birgit Guldhammer Skov overlæge, dr.med. Patologi afdelingen Rigshospitalet Biomarkers lung cancer Last 3-5 years More and more
More informationNational Clinical Trials Network Groups Update Fall 2014
National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationPOSITION DESCRIPTION
POSITION DESCRIPTION Position Title: Reports to: DEVICES CATEGORY MANAGER MANAGER, DEVICES FUNDING Date: September 2014 PHARMAC S MISSION Our legislative objective is: to secure for eligible people in
More informationConsiderations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum
Considerations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum Dr. West: Hello, and welcome. My name is Dr. Jack West, and I m a medical oncologist in Seattle Washington
More informationLung cancer is the leading cause of cancer-related death in the United
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer MARGARET E. M. VAN METER, MD Medical Oncology Fellow Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston,
More informationcure toadvances in Lung Cancer A Patient s Guide
A Patient s Guide toadvances in Lung Cancer The Biology of Lung Cancer New Methods for Detection The Latest Treatment Options Questions to Ask Your Doctor Resources cure C ancer U pdates, R esearch & E
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationPredictive and prognostic markers in. Lung adenocarcinoma - The EGFR and KRAS mutation status and correlations with the prevalence of bone metastases
Predictive and prognostic markers in Lung adenocarcinoma - The EGFR and KRAS mutation status and correlations with the prevalence of bone metastases PhD. Thesis Nóra Bittner MD. Supervisor: Lajos Géczi
More informationEvolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICE NEWS.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer CALEB T. CHU, MD, MPH Postdoctoral Fellow Department of Thoracic/Head and Neck Medical Oncology
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationBritish Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015
0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationTherapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
More informationSystemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationtargeted cancer therapy
LUNG CANCER TREATMENTS What you need to know about... targeted cancer therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationFunding of New Zealand Medical and Scientific Insulin pump and consumables approved
08 August 202 Funding of New Zealand Medical and Scientific Insulin pump and consumables approved PHARMAC is pleased to announce that the approval of an agreement with New Zealand Medical and Scientific
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationImproving EGFR kinase inhibitor design for the targeted treatment of lung cancer.
Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer. Shannon Tarby, Earl Benjamin III, and Ellis Benjamin Department of Chemistry, Richard Stockton College of New Jersey, 101
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationFuture Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
More informationKeywords: Lung Cancer, EGFR kinase, Inflammation
Improving EGFR kinase inhibitor design for the targeted treatment of lung cancer. Shannon Tarby, Earl Benjamin III, and Ellis Benjamin Department of Chemistry, Richard Stockton College of New Jersey, 101
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationEGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004
Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationAdvanced Lung Cancer Treatment - Chemotherapy vs Radiotherapy
Which treatment for advanced lung cancer This information tells you about the treatments for advanced lung cancer. Chemotherapy and radiotherapy can both be used to treat advanced lung cancer. They can
More information